jain.com

2025 ARR target $500m-$1bn

Company: Nebius

Subject kind
guidance
Statement date
2024-10-17
Promised by
2025-12-31
Promised amount
500000000.0 USD
Current status
outcome unconfirmed

What the later record shows

Outcome not yet confirmed

No passage reports Nebius's annualized run-rate revenue at the end of 2025. A May 2025 deck only raised the forecast to $750m-1bn, and the ARR figures that were reported ($1.9bn in March 2026, $3.0bn in June 2026) are for 2026.

“Dec-2024 Mar-2025 Apr-2025 Dec-2025E ~$90m ~$250m ~$310m $750m-1bn”
2025-05-19 · nebius 8-K exhibit (tm2515580d1_ex99-3.htm) View cached copy (2026-10-14)Live source ↗

Checked October 25, 2026 against filings, releases and reporting published after the claim was made. Quotes are verbatim from the linked documents.

The claim, verbatim

Nebius targets 2025 annual recurring revenue of $500 million to $1 billion, depending on how much capital is available for its investment program.

Source (primary)

nebius 8-K exhibit (tm2426436d1_ex99-1.htm) (SEC EDGAR (8-K Ex), press_release)
View cached copy (2026-10-25)Live source ↗

Quote: “2025 ARR $500 - 1,000m 2 ... (2) Depending on the amount of capital available to cover the company's investment program”

How we checked this

This claim has not yet been checked assertion-by-assertion against its source. It carries a cited source and quote, but the deeper check has not run. When it does, the result appears here whatever it says.

Additional evidence

confirms nebius 8-K exhibit (tm2426436d1_ex99-1.htm)

Quote: “2025 ARR $500 - 1,000m 2 ... (2) Depending on the amount of capital available to cover the company's investment program”

View cached copy (2026-10-25)Live source ↗

Record of changes

October 25, 2026 — stated
Automated extraction from the cited source. Recorded automatically from the cited source when it was published, then queued for evidence review.
October 25, 2026 — outcome unconfirmed
Automated extraction from the cited source. Recorded automatically from the cited source when it was published, then queued for evidence review.